ATE495269T1 - Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen - Google Patents
Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungenInfo
- Publication number
- ATE495269T1 ATE495269T1 AT06777334T AT06777334T ATE495269T1 AT E495269 T1 ATE495269 T1 AT E495269T1 AT 06777334 T AT06777334 T AT 06777334T AT 06777334 T AT06777334 T AT 06777334T AT E495269 T1 ATE495269 T1 AT E495269T1
- Authority
- AT
- Austria
- Prior art keywords
- adarb2
- disease
- alzheimer
- neurodegenerative diseases
- diagnostic
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 102100024692 Double-stranded RNA-specific editase B2 Human genes 0.000 title 1
- 101000686486 Homo sapiens Double-stranded RNA-specific editase B2 Proteins 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 101150102859 ADARB2 gene Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000008482 dysregulation Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
- C12Q2535/101—Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69086205P | 2005-06-16 | 2005-06-16 | |
| EP05105316 | 2005-06-16 | ||
| PCT/EP2006/063215 WO2006134128A2 (en) | 2005-06-16 | 2006-06-14 | Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE495269T1 true ATE495269T1 (de) | 2011-01-15 |
Family
ID=35355216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06777334T ATE495269T1 (de) | 2005-06-16 | 2006-06-14 | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100008921A1 (de) |
| EP (1) | EP1891241B1 (de) |
| JP (1) | JP2008546379A (de) |
| AT (1) | ATE495269T1 (de) |
| DE (1) | DE602006019582D1 (de) |
| WO (1) | WO2006134128A2 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008152146A1 (en) * | 2007-06-13 | 2008-12-18 | Biocortech | Peripherical tissue sample containing cells expressing the 5htr2c and/or adars as markers of the alteration of the mechanism of the 5htr2c mrna editing and its applications |
| CA2692861A1 (en) | 2007-07-10 | 2009-01-15 | Neurim Pharmaceuticals (1991) Ltd. | Cd44 splice variants in neurodegenerative diseases |
| EP2202321A1 (de) * | 2008-12-17 | 2010-06-30 | Biocortech | Beurteilung des potentiellen Risikos von durch Arzneimittel ausgelösten Stimmungsstörungen und Selbstmord, Verwendung einer dafür vorgesehenen Plattform |
| US11160893B2 (en) | 2017-06-23 | 2021-11-02 | Allied Bioscience, Inc. | Infection control method and system |
| EP3658172A4 (de) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| WO2024255822A1 (zh) * | 2023-06-15 | 2024-12-19 | 上海魁特迪生物科技有限公司 | Dir结合剂及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763174A (en) * | 1994-02-17 | 1998-06-09 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
| DE4438391C2 (de) | 1994-10-27 | 1997-07-03 | Evotec Biosystems Gmbh | Vorrichtung zur Bestimmung stoffspezifischer Parameter eines oder weniger Moleküle mittels Korrelations-Spektroskopie |
| EP0836090A1 (de) | 1996-10-12 | 1998-04-15 | Evotec BioSystems GmbH | Probenanalyseverfahren durch Bestimmung der spezifischen Helligkeitsverteilung von Teilchen |
| DE19649048C1 (de) | 1996-11-27 | 1998-04-09 | Evotec Biosystems Gmbh | Verfahren zur Unterscheidung oder Erfassung von Partikeln in einer Probe durch Identifizierung von Signalabschnitten zeitaufgelöster, optischer Rohsignale aus der Probe auf Basis von Einzelphotonendetektion |
| EP0945718A1 (de) | 1998-03-21 | 1999-09-29 | Evotec BioSystems AG | Ein Verfahren zur Probencharakterisierung durch Bestimmung einer Funktion mindestens einer spezifischen Eigenschaft von Einheiten der Probe |
| ATE208037T1 (de) | 1997-12-23 | 2001-11-15 | Evotec Biosystems Ag | Verfahren zum nachweis von reaktionen mittels koinzidenzanalyse |
| DK1157267T3 (en) | 1999-03-03 | 2017-01-23 | Olympus Corp | Method for fluorescence binding assay |
| WO2000066985A1 (en) | 1999-04-29 | 2000-11-09 | Evotec Biosystems Ag | A method of characterizing fluorescent molecules or other particles using generating functions |
| US6690463B2 (en) | 2000-02-10 | 2004-02-10 | Evotec Biosystems Ag | Fluorescence intensity and lifetime distribution analysis |
| DE60102797T2 (de) | 2000-02-10 | 2005-09-08 | Evotec Oai Ag | Fluoreszenzintensitätsanalyse unter verwendung einer vielzahl von verteilungen: konkurrierende bestimmung von diffusionszeiten und molekularer helligkeit |
| DE10030798A1 (de) | 2000-06-29 | 2002-01-10 | Evotec Analytical Sys Gmbh | Kompetitives Assay-Verfahren |
| DE60125783T2 (de) | 2000-08-11 | 2007-10-18 | Evotec Ag | Verfahren zum nachweis von acetylase oder deacetylase-aktivität in einem immunoassay |
-
2006
- 2006-06-14 WO PCT/EP2006/063215 patent/WO2006134128A2/en not_active Ceased
- 2006-06-14 US US11/922,060 patent/US20100008921A1/en not_active Abandoned
- 2006-06-14 DE DE602006019582T patent/DE602006019582D1/de active Active
- 2006-06-14 EP EP06777334A patent/EP1891241B1/de active Active
- 2006-06-14 JP JP2008516310A patent/JP2008546379A/ja not_active Withdrawn
- 2006-06-14 AT AT06777334T patent/ATE495269T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006019582D1 (de) | 2011-02-24 |
| JP2008546379A (ja) | 2008-12-25 |
| WO2006134128A2 (en) | 2006-12-21 |
| EP1891241B1 (de) | 2011-01-12 |
| WO2006134128A3 (en) | 2007-03-08 |
| US20100008921A1 (en) | 2010-01-14 |
| EP1891241A2 (de) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE461941T1 (de) | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation | |
| EA200700083A1 (ru) | Антитела, направленные против бета-амилоидного пептида, и способы их применения | |
| WO2001075454A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| ATE361067T1 (de) | Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen | |
| WO2005108999A3 (en) | Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease | |
| ATE530667T1 (de) | Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit | |
| CO6230998A2 (es) | Un metodo para aislar una molecula de enlace especifico dericado de desordenes asociados a proteinas, moleculas de enlace especificas y objetivos | |
| DE602006019582D1 (de) | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen | |
| WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| ATE449964T1 (de) | DIAGNOSTISCHE VERWENDUNG VON ßENSADIN-0477ß FÜR NEURODEGENERATIVE ERKRANKUNGEN | |
| WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| ATE534751T1 (de) | Verwendung von prkx zur diagnose und therapie von alzheimer krankheit | |
| ATE464567T1 (de) | Diagnostische und therapeutische verwendung von f-box-proteinen bei morbus alzheimer und verwandten neurodegenerativen erkrankungen | |
| ATE458834T1 (de) | Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten | |
| WO2006131562A3 (en) | Diagnostic and therapeutic target cdc2l6 gene and proteins for neurodegenerative diseases | |
| ATE316657T1 (de) | Diagnostische und therapeutische verwendung des caps | |
| DE60314497D1 (de) | Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten | |
| DK1379882T3 (da) | Diagnostisk og terapeutisk anvendelse af et nuclearbegrænset protein til Alzheimers syge og beslægtede neurodegenerative forstyrrelser | |
| WO2006091964A8 (en) | Regulators of protein misfolding and aggregation and methods of using the same | |
| WO2005071418A3 (en) | Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases | |
| WO2003100092A3 (en) | Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases | |
| WO2003085131A3 (en) | Diagnostic and therapeutic use of vault polynucleotides and proteins for neurodegenerative diseases | |
| ATE404677T1 (de) | Behandlungsverfahren unter verwendung von 17906 und dessen anwendungen | |
| WO2004047854A3 (en) | Methods for the treatment of alzheimers disease and compositions therefore | |
| ATE501437T1 (de) | Camp-reguliertes phosphoprotein für die diagnose und behandlung von neurodegenerativen krankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |